Data-Gouv-ML/pcri-informations-sur-les-projets-laureats huggingface dataset:
Unlock the full power of your Point of Sales (Salesdat)

Framework: Horizon 2020 — Industrial Leadership
Programme: Information and Communication Technologies
Action type: SME instrument
Countries involved: Spain
Call: Open Disruptive Innovation Scheme (implemented through the SME instrument) (H2020-SMEINST-1-2015, 2015)
Start date: 2015-07-01
End date: 2015-12-31
Duration (months): 6.0
Total project cost (EUR): 71429.0
EU funding (EUR): 50000.0
Participants: 1
Project status: CLOSED

The Luntarium new web and mobile application simplify work for sales reps, stockers and merchandisers selling consumer goods into retail stores and supermarkets while giving full visibility to managers at head office. The software is an innovative and disruptive web platform and mobile technology solution targeted to mass consumer products companies in the EU. The application has high powerful tools in a simple user interface that allow companies monitor prices, out of stock, product availability, product range control, geotagged photos of store fronts, shelves or promotional materials and more for brands and its competition in real time. It has integrated collaboration features like messages, announcements and client notes are a great tool for team management while all reps activities are Geo tagged and monitor. With the tool teams can perform surveys, audits and order management activities. The prototype software was built with Wisis Rapid Ajax Application Framework developed by our key partner Infologic S.A., leading edge technology for extreme fast customized software development at the highest level of client expectations using the latest Java / J2EE and Ajax technology environment. The need of this unique software was discover while working closely with Group Danone, multinational market leader of daily and mass market products. Danone needed to boost sales at the point of sales, and responds to its competitors and leverage their customers’ with new ways of shopping by mobilizing their customer experience, it’s partner’s stores, and it’s entire value chain. The client could not find any software available on the market. The software prototype has been already implemented successfully in 2014 at Danone Argentina with excelent feedback from 50 fields’reps. We need to complete our feasibility study to introduce this unique software in the EU. Luntarium development and marketing teams will further developed the feseability report and business plan.

Keywords: innovation technology software point of sales platform,moble application
Understanding the evolution of plasmid-mediated antibiotic resistance in real life scenarios (PLASREVOLUTION)

Framework: Horizon 2020 — Excellent Science
Programme: European Research Council (ERC)
Theme: European research council
Destination: Starting grants
Action type: ERC actions
Panel: Environmental Biology, Ecology and Evolution
Panel description: Ecology, biodiversity, environmental change, evolutionary biology, behavioural ecology, microbial ecology, marine biology, ecophysiology, theoretical developments and modelling
Countries involved: Spain
Call: ERC Starting Grant (ERC-2017-STG, 2017)
Start date: 2018-02-01
End date: 2024-01-31
Duration (months): 72.0
Total project cost (EUR): 1497314.0
EU funding (EUR): 908791.98
Participants: 2
Project status: SIGNED

Antibiotics are essential tools in modern medicine and are indispensable not only for the treatment of infectious diseases but also to support other key interventions such as surgery and cancer chemotherapy. However, the extensive and inappropriate use of antibiotics has fuelled the spread of resistance mechanisms in pathogenic bacteria, leading to the dawn of a post-antibiotic era. Plasmids play a pivotal role in the evolution of antibiotic resistance (AR) because they drive the horizontal transfer of resistance genes between pathogenic bacteria by conjugation. Some of these plasmid-bacterium associations become particularly successful, creating superbugs that spread uncontrollably in clinical settings. The rise of these clones is mainly constricted because plasmids entail a fitness cost when they arrive in a new bacterial host. This cost can be subsequently alleviated through compensatory adaptation during plasmid-bacterium coevolution. Despite the importance of this cost-compensation dynamic in the evolution of plasmid-mediated AR, it remains completely unexplored in clinical contexts. In this project I plan to bridge this gap by exploring the genetic basis underlying the evolution of plasmid-mediated AR in clinically relevant scenarios. We will study, for the first time, the intra-patient transmission, fitness cost and adaptation of AR plasmids in the gut microbiome of hospitalized patients (obj. 1). We will analyse the molecular mechanisms that determine the success of AR plasmids and bacterial clone associations (obj. 2). Finally, we will develop new technology to test how antibiotic treatments affect AR plasmids dynamics in the gut microbiome at an unprecedentedly high-resolution (obj. 3). This ground-breaking project will allow a new understanding of the evolution of plasmid-mediated AR in real life, opening new research avenues and providing a major step towards meeting one of the central challenges facing our society: controlling the spread of AR.

Keywords: antibiotic resistance
Surgify Safety Burr (SSB)

Framework: Horizon 2020 — Industrial Leadership
Programme: Innovation in SMEs
Action type: SME instrument
Countries involved: Finland
Call: SME instrument (H2020-SMEInst-2018-2020-1, 2019)
Start date: 2019-08-01
End date: 2020-01-31
Duration (months): 6.0
Total project cost (EUR): 71429.0
EU funding (EUR): 50000.0
Participants: 1
Project status: CLOSED

Surgify’s mission is to make bone surgery safer around the globe. Our product - Surgify Safety Burr (SSB) enables surgeons to cut bone safely, accurately and fast without compromising the safety of important soft structures. The core innovation is in the mechanisms of a disposable cutting tip of a surgical drill. SSB automatically covers the cutting edges of the small drill tip when it comes into contact with soft tissue. Surgify has successfully tested the technology in preclinical setups with human and animal cadavers (TRL:6). Based on non-clinical trials by surgeons, Surgify estimates that SSB can realistically reduce the risk of soft tissue injuries with 80% - 91%. Academic research shows that patients without dural tears have 42% - 97% less complications. World-famous neurosurgeon, Professor Juha Hernesniemi has stated: “Breakthrough!” The first target applications (est. potential €640M) are skull, spine and ear procedures, which account for 55% of the bone cutting disposable attachment market (€1.2B). In the future, Surgify can expand to other fields of surgery as well as robotic surgery applications. Surgify has multiple ongoing pilots and signed letters of intent worth €355k / year. In September 2017, Surgify’s CEO received the prestigious MIT Technology Review Innovators Under 35 Europe award. In December 2018, Surgify was named as one of the 24 winners of the European Venture Contest, arranged by TechTour. The SME Phase 1 funding is critical for Surgify. It will be used to further develop a focused, detailed and achievable commercial and operational business plan that adds necessary expertise and scales the sales and revenue delivery to deliver the 2021/2022 goals. With this funding, we can find commercial manufacturing partners, complete a detailed market analysis, interview leading surgeons and prepare necessary commercial plan with financial forecasts to raise SME Phase 2 and/or VC funding for commercial product launch by the end of 2019.

Keywords: surgical device,surgical instrument,bone surgery,power tools,spine surgery,neurosurgery,ent surgery
AnchorGuardian, providing safety during anchoring by monitoring the position and absolute movement of a ships anchor. (AnchorGuardian)

Framework: Horizon 2020 — Industrial Leadership
Programme: Innovation in SMEs
Action type: SME instrument
Countries involved: Switzerland
Call: SME instrument (H2020-SMEInst-2018-2020-1, 2019)
Start date: 2019-07-01
End date: 2019-12-31
Duration (months): 6.0
Total project cost (EUR): 71429.0
EU funding (EUR): 50000.0
Participants: 1
Project status: CLOSED

Swiss Ocean Tech is a start-up with the purpose to create the very first worldwide solution for monitoring the position and absolute movements of a ships anchor and predict imminent dragging; AnchorGuardian. AnchorGuardian will provide safety during anchoring for captains, crew, passengers and yacht owners by identifying the dangerous dragging of the anchor. Thereby minimising / eliminating injuries to persons and damage to the ship because of collision or grounding. "Anchoring is the most dangerous condition for a ship" is a statement made by a captain which well summarises the view of an entire industry. Despite groundbreaking inventions in marine navigation such as GPS, radar, depth sounder and other achievements, the anchoring is basically done in the same way as hundreds of years ago. For the first time ever, AnchorGuardian will enable the users to monitor the absolute movement and position of a ships anchor and to receive relevant information whilst laying and lifting the anchor. Sub-meter accuracy with early alarms if the anchor is dragging, independent of any movement of the ship, is provided. Such a monitoring device is not yet available anywhere in the marine industry, and we intend to revolutionise and dominate this market. AnchorGuardian is a disruptive, patented technology and will define the new state-of-the-art. In 10 years, AnchorGuardian shall be recognised as standard yachting equipment for anchoring, the same way as GPS is today recognized in maritime navigation. Market research has been performed and a conceptual model has established proof of technology.

Keywords: anchor monitoring,anchor dragging,maritime security
An accessible and versatile Augmented Reality content creation tool for SMEs and large companies (VISCOPIC Pins)

Framework: Horizon 2020 — Industrial Leadership
Programme: Innovation in SMEs
Action type: SME instrument
Countries involved: Germany
Call: SME instrument (H2020-SMEInst-2018-2020-1, 2019)
Start date: 2019-08-01
End date: 2020-01-31
Duration (months): 6.0
Total project cost (EUR): 71429.0
EU funding (EUR): 50000.0
Participants: 1
Project status: CLOSED

VISCOPIC GmbH was founded in 2016 with the ambition to pave the way for Augmented Reality in the industrial environment. Two years later VISCOPIC developed to one of the most innovative and promising Augmented Reality companies in the world with over a dozen won awards. Companies worldwide are concerned with the digitalisation and thus faced with the challenge of working effectively with the resulting data volumes. Always having the right information at the right place is the key to increased efficiency. Augmented Reality (AR) will play a major role in future business. But for most companies, the implementation of AR is associated with a large financial investment. To lower the entry barrier for companies being interested in AR, VISCOPIC offers with VISCOPIC Pins a simple and versatile AR solution for small and large companies alike. The accessible AR tool makes it easy to learn how to create AR content within an hour - without any previous knowledge. In addition to individual information, multistep instructions can also be created in just a few minutes. Especially the manufacturing industry is highly interested in the increased efficiency and flexibility, that can be achieved by implementing good AR applications. Since VISCOPIC started their business with AR use-case consulting and custom AR software, they are now able to provide a holistic service and an accessible solution for AR content creation. But for most cases an accompanying consultation will not be necessary since VISCOPIC Pins is highly intuitive. This could be achieved by collaborating with many pilot customers (such as Audi, Deutsche Bahn Netz, BMW, VW, TetraPak, Viessmann and more). Hempleton Partners prognoses the market for AR to explode in the next four years and grow worldwide with a CAGR of 85 % to a market size of around € 140 billion by 2022.

Keywords: data visualisation,enhanced learning processes,digitalisation,ar content,tracking technologies,enhanced industry processes
A training network for the design of new synthetic carbohydrate-based vaccines to combat antibiotic resistant Pseudomonas aeruginosa (PAVax)

Framework: Horizon 2020 — Excellent Science
Programme: Marie-Sklodowska-Curie Actions
Theme: Marie Skłodowska-Curie
Destination: Innovative Training Networks (ITN)-European Industrial Doctorates
Action type: Marie Skłodowska-Curie actions
Panel: Chemistry
Countries involved: Italy,Netherlands
Call: Innovative Training Networks (H2020-MSCA-ITN-2019, 2019)
Start date: 2020-03-01
End date: 2024-08-31
Duration (months): 54.0
Total project cost (EUR): 1054239.12
EU funding (EUR): 1054239.12
Participants: 2
Project status: SIGNED

PAVax is a network that will train 4 early-stage researchers (ESRs) on the conception of new synthetic vaccines to combat the antibiotic resistant bacterium Pseudomionas aeruginosa (PA), for which there currently is no adequate vaccine available. This consortium will explore and exploit the use of PA-exopolysaccharides that play a key role in biofilm formation that protects the bacterium from its environment: alginate, Psl and Pel. We will exploit these saccharides to generate novel vaccines targeting these exposed polysaccharides. Next to the isolation of these polysaccharides from the bacteria, we will employ synthetic chemistry to deliver well-defined fragments of these polysaccharides. These will be used to map the interactions of the saccharides with antibodies to inform on the structure of the optimal epitope. We will conjugate the (synthetic) fragments to newly discovered PA proteins to generate conjugate vaccines targeting multiple PA entities. The consortium is formed by an academic partner, Leiden University (NL) and an industrial partner, GSK Vaccines, Siena (IT), harnessing the complementary expertise of both partners to achieve the ambitious goals set. The close collaboration between the two partners will ensure training of the ESRs at the highest level and best synergy possible. The ESRs will receive intersectorial, international and interdisciplinary training in (synthetic) carbohydrate chemistry, vaccine design, protein chemistry and conjugation, biophysical interaction studies, and immunology. With the ever-growing awareness of the importance of carbohydrates in health and disease, and the continuous threat of multidrug resistant bacteria, the skill set acquired by the ESRs will prepare them to face the major scientific and societal challenges ahead and become important players in academic or industrial research in the future

Keywords: bacterial glycans,synthetic chemistry,conjugate vaccines,carbohydrates,structure elucidation,antibodies,pseudomonas aeruginosa,std nmr,carrier proteins
Computational modelling of the human brain lipidome (HumBrain)

Framework: Horizon 2020 — Excellent Science
Programme: Marie-Sklodowska-Curie Actions
Theme: Marie Skłodowska-Curie
Destination: Individual Fellowships (IF)-Reintegration panel
Action type: Marie Skłodowska-Curie actions
Panel: Life Sciences
Countries involved: Denmark
Call: Individual Fellowships (H2020-MSCA-IF-2020, 2020)
Start date: 2022-03-01
End date: 2024-02-29
Duration (months): 24.0
Total project cost (EUR): 207312.0
EU funding (EUR): 207312.0
Participants: 1
Project status: SIGNED

The blood-brain barrier (BBB) is a complex interface that separates the central nervous system (CNS) from the circulatory system and serves to maintain brain homeostasis. There are native P-glycoprotein (P-gp) transporters embedded in the BBB endothelial cell membranes, which play a fundamental role in effluxing out xenobiotics. Such protections come at a steep price, since the BBB is a key roadblock in the delivery of treatments for CNS disorder, including brain tumors and Alzheimer’s, while the P-glycoprotein transporter reduces the effectiveness of chemotherapeutics and is responsible for the development of multidrug resistance (MDR). The HumBrain project will build the first atomistic model of a human P-gp pump embedded in a realistic model of the BBB membrane, and use molecular dynamics simulations in combination with novel free-energy techniques to provide a mechanism for the modulation of the P-gp pump by substrates and inhibitors, in order to address the origins of multidrug resistance and the origins of the high selectivity of the BBB membranes to molecules. This will be complemented by coarse-grained models to address the issue of protein-lipid modulation and alternative ways to turn off the P-gp. The models will be of sufficiently realistic representation to serve as a starting point for translational research to aid in the experimental development of the next generation CNS modulators and targets. The HumBrain project will be carried out by an experienced researcher who worked on membrane proteins during his PhD thesis in the UK and the BBB during his postdoc in the USA in conjunction with an experimental laboratory. The experienced researcher will work with a supervisor in Denmark who has a strong background in modelling complex membranes, including neuronal membranes, as well as membrane proteins, and will benefit from the strong network of simulations present in Denmark, while bringing his expertise from USA and the UK with him.

Keywords: blood brain barrier,efflux pumps,molecular dynamics simulations,membrane permeability,transport kinetics
Deciphering immune evasion of Acute Myeloid Leukemia (DIEAML)

Framework: Horizon 2020 — Excellent Science
Programme: Marie-Sklodowska-Curie Actions
Theme: Marie Skłodowska-Curie
Destination: Individual Fellowships (IF)-Standard European Fellowships
Action type: Marie Skłodowska-Curie actions
Panel: Life Sciences
Countries involved: Germany
Call: Individual Fellowships (H2020-MSCA-IF-2020, 2020)
Start date: 2022-09-01
End date: 2024-12-01
Duration (months): 24.0
Total project cost (EUR): 162806.4
EU funding (EUR): 162806.4
Participants: 1
Project status: SIGNED

Acute Myeloid Leukemia (AML) is the most common adult leukemia, with a high frequency of relapse and mortality. After therapy, the persistence of rare leukemia stem cells (LSCs) with disease initiating and therefore stem cell-like properties is a likely cause for relapse. Therefore, novel therapeutic strategies to specifically eradicate LSCs are urgently needed. Natural Killer-cells (NK-cells) are innate immune cells capable of detecting cell surface ligands to trigger a cytotoxic response against diverse tumor cell types. NK-cells are activated either by missing inhibitory or activating ligands, such as known natural killer group 2D receptor ligands (NKG2DL), which become expressed on target cells upon cellular stress or malignant transformation. The groups of Drs. Trumpp, Lengerke and Salih recently described that LSCs evade the recognition from NK-Cells by repressing NKG2DL expression. Importantly, inhibition of Poly [ADP-ribose] polymerase 1 (PARP1) in a subclass of CD34+ AML patient samples reactivated NKG2DL expression and, when combined with allogeneic NK-Cell therapy, eradicated AML in xenotransplantation models. The goal of this proposal is to systematically discover novel NKG2DL regulators in AML to improve immunotherapeutic therapy options for a broad group of AML patients. I have identified monocytic differentiation and DNA hypermethylation as potentially opposing mechanisms of NKG2DL expression. I will combine single-cell transcriptomic and epigenomic interrogation of AML patient samples to discover how NKG2DL are activated during malignant differentiation and how these processes are impeded by DNA hypermethylation. These approaches, together with genome-wide CRISPR-dCas9 gain of function screens, will help identify master regulators of NKG2DL expression. Lastly, validation of these regulators in AML patient samples will expose vulnerabilities of AML for NK-cell based therapies and elaborate on the previously identified link with AML stemness.

Keywords: leukemia stem cells,acute myeloid leukemia,nkg2dl regulation,nk cell therapy,immune evasion,aml differentiation,dna hypermethylation,aml single cell transcriptomics,methylomics,crispr dcas9
Novel, high-throughput compatible dry transfer approach to enable high performance, suspended CVD 2D material heterostructure electronic devices and their applications (dryhetero)

Framework: Horizon 2020 — Excellent Science
Programme: Marie-Sklodowska-Curie Actions
Theme: Marie Skłodowska-Curie
Destination: Individual Fellowships (IF)-Standard European Fellowships
Action type: Marie Skłodowska-Curie actions
Panel: Information Science and Engineering
Countries involved: Switzerland
Call: Individual Fellowships (H2020-MSCA-IF-2020, 2020)
Start date: 2021-12-01
End date: 2023-11-30
Duration (months): 24.0
Total project cost (EUR): 191149.44
EU funding (EUR): 191149.44
Participants: 1
Project status: SIGNED

Ultra-fast computation, lower power consumption and novel electronic device concepts – these are three primary advantages for a hybrid integration of two-dimensional (2D) materials with existing CMOS technologies. Stacking of semiconducting and insulating 2D materials has been proven to offer state-of-the-art performance metrics that exceed the current standards set by 3D materials. Novel, high-throughput techniques to realize ultra-clean, dry-transferred 2D material heterostructures are highly sought-after to enable the paradigm shift in advanced material technologies. In this proposal ‘dryhetero’, we propose a novel approach to realize suspended 2D material heterostructures. Our approach is a unique, high-yield, nanostructure assembly solution that offers high-throughput compatibility and allows for the fabrication of clean, 2D material heterostructures to enable high performance metric 2D material electronic devices and sensors. In a two-step process, first, we perform patterning of as-grown 2D material growth substrates and suspension of 2D materials. Second, the suspended 2D material films are transferred onto receiving electrodes – completing the dry transfer of the 2D material. Repeating the transfer process with other 2D materials allows for the formation of 2D material heterostructures for low scale integrated electronic devices, such as sensors. Our two-step approach facilitates advanced, integrated process control of 2D materials using Raman spectroscopy and functional testing & calibration pre/post the dry transfer process. We identify this proposal strategically positioned within the current work programme’s focus area on ‘digitising and transforming European industry and services’. We foresee the proposal to benefit the European unions’ focus area on ‘nanotechnologies, advanced materials, advanced manufacturing and processing & biotechnology’ (LEIT-NMBP).

Keywords: 2d materials,cvd graphene,hbn heterostructure,dry transfer,advanced manufacturing